NEW YORK (
The short-term view of LLY, above, presents some negatives. We can see, for instance, that LLY broke support around $79, but it has managed to rally back to its 50-day moving average. The On-Balance-Volume (OBV) line peaked in July and has been eroding since. It would be nice to cite a bullish divergence, but we don't have one vs. the momentum study. What LLY has going for it is a pretty strong fourth quarter rally for the overall market and a biopharmaceutical industry that could manage to carry it along for a rally towards $90.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks with serious upside potential in the next 12-months.
However, the longer-term perspective on LLY, above, points to problems ahead, in our opinion. LLY had been climbing nicely above the rising 40-week moving average until now, and has begun testing that average. A close below the 40-week moving average at some point would be a negative. Note that the OBV line has been...